» Articles » PMID: 30671611

Pregnancy-associated Osteoporosis: a UK Case Series and Literature Review

Overview
Journal Osteoporos Int
Date 2019 Jan 24
PMID 30671611
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Mini Abstract: Pregnancy-associated osteoporosis (PAO) is a rare syndrome affecting women during late pregnancy and the early postpartum period. We set out to review the clinical features of ten cases of PAO from a single UK centre. Patients had attended the Royal National Hospital for Rheumatic Diseases, Bath (RNHRD) between January 2000 and June 2016. The principal criterion for inclusion was the occurrence of low trauma fractures either during pregnancy or the immediate post-partum period. Data were obtained from retrospective review of medical notes. Bone mineral density (BMD) was measured using dual-energy X-ray absorptiometry (Hologic ®Discovery system) at the lumbar spine and hip. Data pertaining to the pregnancy, as well as type and duration of treatment received, were reviewed. All ten cases presented with vertebral fractures. In four patients, no risk factors for fracture other than pregnancy or breastfeeding could be identified. Four patients were found to have vitamin D insufficiency at the time of diagnosis, and a further two patients had received treatment with low molecular weight heparin (LMWH). In one case, further investigation led to a diagnosis of osteogenesis imperfecta (OI) confirmed on genetic testing. In terms of treatment, eight out of the ten patients in this series received a bisphosphonate, most commonly risedronate due to its relatively short skeletal retention time. Clinicians should be aware of PAO, a rare but recognised complication of pregnancy. The condition should be especially considered in women presenting with new onset back pain in pregnancy or the postpartum period.

Citing Articles

Postpartum multiple vertebral fractures in a patient with osteogenesis imperfecta type I: A case report and literature review.

Miyazaki Y, Hosokawa M, Kudo S, Onuma T, Orisaka M, Yoshida Y Case Rep Womens Health. 2024; 44:e00666.

PMID: 39635157 PMC: 11616087. DOI: 10.1016/j.crwh.2024.e00666.


Rehabilitation of Pregnancy and Lactation-Associated Osteoporosis and Vertebral Fractures: A Case Report.

Sahni P, Edeer A, Lindsay R HSS J. 2024; 20(2):298-305.

PMID: 39281988 PMC: 11393619. DOI: 10.1177/15563316231167148.


A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database.

Xu H, Xu N, Wang Y, Zou H, Wu S Front Pharmacol. 2024; 15:1442002.

PMID: 39188956 PMC: 11345143. DOI: 10.3389/fphar.2024.1442002.


Minodronate for severe multiple vertebral fractures due to pregnancy- and lactation-associated osteoporosis: a case report and literature review.

Ota K, Asanuma Y, Hirasawa H, Ohta H, Takahashi T Ther Adv Musculoskelet Dis. 2024; 16:1759720X241259897.

PMID: 39156664 PMC: 11327966. DOI: 10.1177/1759720X241259897.


Preconception underweight impact on postnatal osteoporotic fracture: a retrospective cohort study using Japanese claims data.

Kaneko K, Suto M, Miyagawa E, Mikami M, Nakamura Y, Murashima A BMC Pregnancy Childbirth. 2024; 24(1):315.

PMID: 38664710 PMC: 11044344. DOI: 10.1186/s12884-024-06514-y.


References
1.
Pearson D, Kaur M, San P, Lawson N, Baker P, Hosking D . Recovery of pregnancy mediated bone loss during lactation. Bone. 2004; 34(3):570-8. DOI: 10.1016/j.bone.2003.11.005. View

2.
Handschin A, Trentz O, Hoerstrup S, Kock H, Wanner G, Trentz O . Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg. 2004; 92(2):177-83. DOI: 10.1002/bjs.4809. View

3.
OSullivan S, Grey A, Singh R, Reid I . Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int. 2006; 17(7):1008-12. DOI: 10.1007/s00198-006-0112-3. View

4.
Ornoy A, Wajnberg R, Diav-Citrin O . The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol. 2006; 22(4):578-9. DOI: 10.1016/j.reprotox.2006.05.009. View

5.
Levy S, Fayez I, Taguchi N, Han J, Aiello J, Matsui D . Pregnancy outcome following in utero exposure to bisphosphonates. Bone. 2008; 44(3):428-30. DOI: 10.1016/j.bone.2008.11.001. View